Evidence map›Paper›PMID 37467188›Full record

ArticlePloS one2023

Antigen concentration, viral load, and test performance for SARS-CoV-2 in multiple specimen types.

Allison Golden, Michelle Oliveira-Silva, Hannah Slater, Alexia Martines Vieira, Pooja Bansil, Emily Gerth-Guyette, Brandon T Leader, Stephanie Zobrist, Alan Kennedy Braga Ferreira, Erika Crhistina Santos de Araujo and 17 more

Abstract read
In one paragraph

Article in PloS one, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Allison GoldenDiagnostics, PATH, Seattle, Washington, United States of America.ORCID 0000-0001-6891-5176
Michelle Oliveira-SilvaCentro de Pesquisa em Medicina Tropical (CEPEM), Porto Velho, Rondônia, Brazil.
Hannah SlaterDiagnostics, PATH, Seattle, Washington, United States of America.
Alexia Martines VieiraCentro de Pesquisa em Medicina Tropical (CEPEM), Porto Velho, Rondônia, Brazil.
Pooja BansilDiagnostics, PATH, Seattle, Washington, United States of America.
Emily Gerth-GuyetteDiagnostics, PATH, Seattle, Washington, United States of America.
Brandon T LeaderDiagnostics, PATH, Seattle, Washington, United States of America.
Stephanie ZobristDiagnostics, PATH, Seattle, Washington, United States of America.
Alan Kennedy Braga FerreiraCentro de Pesquisa em Medicina Tropical (CEPEM), Porto Velho, Rondônia, Brazil.
Erika Crhistina Santos de AraujoCentro de Pesquisa em Medicina Tropical (CEPEM), Porto Velho, Rondônia, Brazil.
Catherine Duran de Lucena CruzCentro de Pesquisa em Medicina Tropical (CEPEM), Porto Velho, Rondônia, Brazil.
Eduardo GarbinCentro de Pesquisa em Medicina Tropical (CEPEM), Porto Velho, Rondônia, Brazil.
Greg T BiziljDiagnostics, PATH, Seattle, Washington, United States of America.
Sean J CarlsonDiagnostics, PATH, Seattle, Washington, United States of America.
Mariana SagalovskyDiagnostics, PATH, Seattle, Washington, United States of America.
Sampa PalDiagnostics, PATH, Seattle, Washington, United States of America.
Vin GuptaAmazon.com, Seattle, Washington, United States of America.
Leo WolanskyPandemic Prevention Institute, The Rockefeller Foundation, New York City, New York, United States of America.
David S BoyleDiagnostics, PATH, Seattle, Washington, United States of America.ORCID 0000-0003-4019-9037
Deusilene Souza Vieira Dall'AcquaFundação Oswaldo Cruz (FIOCRUZ), Porto Velho, Rondônia, Brazil.
Felipe Gomes NavecaInstituto Leônidas e Maria Deane (ILMD), Fundação Oswaldo Cruz (FIOCRUZ), Manaus, Amazonas, Brazil.
Valdinete Alves do NascimentoInstituto Leônidas e Maria Deane (ILMD), Fundação Oswaldo Cruz (FIOCRUZ), Manaus, Amazonas, Brazil.
Juan Miguel Villalobos SalcedoFundação Oswaldo Cruz (FIOCRUZ), Porto Velho, Rondônia, Brazil.
Paul K DrainDepartment of Global Health, University of Washington, Seattle, Washington, United States of America.ORCID 0000-0002-9569-4097
Alexandre Dias Tavares CostaInstituto Carlos Chagas (ICC), Fundação Oswaldo Cruz (FIOCRUZ), Curitiba, Paraná, Brazil.ORCID 0000-0001-8434-2152
Dhélio PereiraCentro de Pesquisa em Medicina Tropical (CEPEM), Porto Velho, Rondônia, Brazil.ORCID 0000-0002-7761-5498
Gonzalo J DomingoDiagnostics, PATH, Seattle, Washington, United States of America.ORCID 0000-0002-1004-4395

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The relationship between N-antigen concentration and viral load within and across different specimens guides the clinical performance of rapid diagnostic tests (RDT) in different uses. A prospective study was conducted in Porto Velho, Brazil, to investigate RDT performance in different specimen types as a function of the correlation between antigen concentration and viral load. The study included 214 close contacts with recent exposures to confirmed cases, aged 12 years and older and with various levels of vaccination. Antigen concentration was measured in nasopharyngeal swab (NPS), anterior nares swab (ANS), and saliva specimens. Reverse transcriptase (RT)-PCR was conducted on the NPS and saliva specimens, and two RDTs were conducted on ANS and one RDT on saliva. Antigen concentration correlated well with viral load when measured in the same specimen type but not across specimen types. Antigen levels were higher in symptomatic cases compared to asymptomatic/oligosymptomatic cases and lower in saliva compared to NPS and ANS samples. Discordant results between the RDTs conducted on ANS and the RT-PCR on NPS were resolved by antigen concentration values. The analytical limit-of-detection of RDTs can be used to predict the performance of the tests in populations for which the antigen concentration is known. The antigen dynamics across different sample types observed in SARS-CoV-2 disease progression support use of RDTs with nasal samples. Given lower antigen concentrations in saliva, rapid testing using saliva is expected to require improved RDT analytical sensitivity to achieve clinical sensitivity similar to rapid testing of nasal samples.

Indexed as

COVID-19SARS-CoV-2HumansNasopharynxProspective StudiesSalivaSensitivity and SpecificitySerologic TestsSpecimen HandlingViral Load

Identifiers

PMID37467188
PMCPMC10355390

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.